Thema: US09073M1045
Bio-Techne, US09073M1045
wall-street-621097_1920.jpg - Foto: THN
Bio-Techne stock trades at EUR 64.94 in late Wednesday session
Bio-Techne develops reagents, instruments and precision diagnostics for research and clinical testing. Its portfolio supports drug discovery and laboratory work.
ad-hoc-news.de, vor 52 Minuten
Bio-Techne, US09073M1045
17 analysts give Bio-Techne stock a USD 68.92 average target ...
Fiscal 2026 revenue was USD 1.22 billion, with 32.20 percent adjusted margin. Bio-Techne stock costs EUR 64.58 on October 20, 2026 at 7:49 p.m. CEST.
ad-hoc-news.de, 20.10.26 19:54 Uhr
Bio-Techne, US09073M1045
Bio-Techne stock has a November 4, 2026 reporting date
Revenue is estimated at USD 292.61 million for the next quarter. Bio-Techne stock last stood at EUR 64.57 on October 16, 2026.
ad-hoc-news.de, 17.10.26 18:59 Uhr
Bio-Techne, US09073M1045
Bio-Techne stock sits 0.22 percent below its 52-week high ...
Analysts set a USD 68.92 target on October 14, 2026. Bio-Techne stock costs EUR 64.71 on October 15, 2026, up 0.05 percent on Nasdaq.
ad-hoc-news.de, 15.10.26 18:44 Uhr
Bio-Techne, US09073M1045
Bio-Techne approves Merck deal: what it means for Bio-Techne ...
Merck sets USD 73.00 cash value for Bio-Techne stock. Fiscal 2026 adjusted earnings per share was USD 0.52 and operating margin was 32.20 percent.
ad-hoc-news.de, 07.10.26 07:00 Uhr
Bio-Techne’s, Strategic
Bio-Techne’s Strategic Pivot: Can Automation and High-Margin ...
